Clinical trial · Interventional
Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma
Enrichment and Purging of Stem Cells in the Treatment of Non-Hodgkin's Lymphoma
NCT00186355CI-TRIAL-00006895completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the role of purging the hematopoietic cell graft on outcomes for non-Hodgkin's Lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, Non-Hodgkin | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| high dose chemo then auto hematopoietic cell transplant | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- PCR positivity in peripheral blood cell collections after cyclophosphamide
Secondary outcomes (1)
- measure
- Enrichment of hematopoietic stem cells
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 4 Weeks
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria:- relapsed NHL Exclusion Criteria:- liver dysfunction
References
Publications (0)
Data not yet available
No reference posted for this study.